Breast cancer patients with hormone neoadjuvant bridging therapy due to asymptomatic Corona virus infection. Case report, clinical and histopathologic findings.
Breast cancer patients with hormone neoadjuvant bridging therapy due to asymptomatic Corona virus infection. Case report, clinical and histopathologic findings.
复制标题
DOI：
10.1016/j.ijscr.2020.10.020
复制
发表时间：
2020
影响因子：
0.6
通讯作者：
Vanni G
中科院分区：
文献类型：
--
作者：
Pellicciaro M;Granai AV;Marchese G;Materazzo M;Cotesta M;Santori F;Giacobbi E;Servadei F;Grelli S;Perretta T;Meucci R;Pistolese CA;Vanni G
受新冠肺炎疫情影响，肿瘤治疗大幅放缓。根据科学建议，乳腺癌的管理已经发生了变化。同时感染COVID-19的乳腺癌患者可能会接受延迟治疗。治疗延迟可能会影响乳腺癌的分期。COVID-19大流行期间的乳腺癌管理发生了变化，对于同时发生肿瘤的COVID-19患者，强烈建议首先治疗Sars-CoV-2感染。我们报告了一例53岁女性早期乳腺癌并同时无症状SARS-CoV-2感染的病例。根据COVID-19乳腺癌的建议，她接受了激素新辅助治疗，作为手术的桥接治疗。确诊六个月后，在病毒根除后，患者接受了乳房手术。手术标本和前哨淋巴结均未发现SARS-CoV-2 RNA，但有微转移的报道。末次随访时，患者临床情况良好，开始辅助化疗。COVID-19的爆发决定了临时建议的发布，导致乳腺癌患者广泛使用新辅助化疗。虽然内分泌治疗是辅助治疗的主要手段，但其在新辅助治疗方案中的作用尚不清楚。尤其是无症状的COVID-19合并早期乳腺癌患者，在无法监测肿瘤反应的情况下，应优先进行术前清醒手术。
Oncological treatments experienced a significant slowdown due to COVID-19 pandemic. Breast cancer management has changed according to scientific recommendations. Breast cancer patients with simultaneous COVID-19 could receive delayed treatments. Treatments delay could impact breast cancer staging. Breast cancer management during COVID-19 pandemic has changed and in case of COVID-19 patients with simultaneous neoplasia, it has been strongly recommended to treat Sars-CoV-2 infection firstly. We reported a case of a 53-years-old women with early breast cancer and simultaneous asymptomatic SARS-CoV-2 infection. According to COVID-19 breast cancer recommendations she underwent hormone neoadjuvant treatment as a bridging therapy for surgery. Six months from the diagnosis, after virus eradication, patient underwent breast surgery. No SARS-CoV-2 RNA was found both in the surgical specimen and sentinel lymph node but micrometastasis were reported. During the last follow-up, the patient was in good clinical condition and started the adjuvant chemotherapy. COVID-19 outbreak determined the publication of temporary recommendation leading to an extensive use of neoadjuvant chemotherapy in breast cancer patients. Although endocrine therapy is a mainstay in the adjuvant treatment, its role in the neoadjuvant schedule is unclear. Upfront awake surgery should be preferred especially in asymptomatic COVID-19 patient with early breast cancer when monitoring of tumor response is not feasible.
登录
查看更多内容
影响因子：
1.9
作者：
Buonomo, O;Granai, AV;Roselli, M
通讯作者：
Roselli, M
影响因子：
2.3
作者：
Buonomo, Oreste Claudio;Materazzo, Marco;Vanni, Gianluca
通讯作者：
Vanni, Gianluca
影响因子：
2.3
作者：
Vanni, Gianluca;Materazzo, Marco;Buonomo, Oreste Claudio
通讯作者：
Buonomo, Oreste Claudio
影响因子：
6.2
作者：
Ferroni, Patrizia;Roselli, Mario;Guadagni, Fiorella
通讯作者：
Guadagni, Fiorella
影响因子：
3.4
作者：
Guerini-Rocco, Elena;Taormina, Sergio Vincenzo;Barberis, Massimo
通讯作者：
Barberis, Massimo